QQ客服 官方微博 反馈留言

	Open label, multi-center, prospective study to investigate the efficacy and safety of osimertinib in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI (APOLLO Study, NCT02972333)
	Wang, L.; Xing, L.; Cao, L.; Wang, X.; Feng, J.; Shu, Y.; Shi, Y.; Song, Y.; Yu, J.
	2017
会议名称	ANNALS OF ONCOLOGY
会议日期	2017-04-01
收录类别	CPCI-S
URL标识	查看原文
内容类型	会议论文
URI标识	http://www.corc.org.cn/handle/1471x/6365283
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Wang, L.,Xing, L.,Cao, L.,et al. Open label, multi-center, prospective study to investigate the efficacy and safety of osimertinib in brain metastases from patients with EGFR T790M positive NSCLC who have received prior therapy with an EGFR-TKI (APOLLO Study, NCT02972333)[C]. 见:ANNALS OF ONCOLOGY. 2017-04-01.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。